AIDS 2006; Toronto, Canada; August 13-18, 2006

Key Links:

By Topic:


See Also
A dual-NRTI backbone for multiple patients >

UNBP3028 1/17

The Body PRO Covers: The XVI International AIDS Conference

Ritonavir-Boosted Tipranavir More Effective Than Other Ritonavir-Boosted PIs in HIV-Infected Patients With PI Resistance

August 17, 2006

This was a fairly large, clinic-based, retrospective analysis1 of virologic response rates to a broad range of ritonavir (RTV, Norvir)-boosted protease inhibitors (PIs), including saquinavir (SQV, Invirase) 1,000 mg twice daily, indinavir (IDV, Crixivan) 800 mg twice daily, lopinavir (LPV) 400 mg twice daily, amprenavir (APV, Agenerase) 600 mg twice daily, atazanavir (ATV, Reyataz) 300 mg once daily and tipranavir (TPV, Aptivus) 500 mg twice daily.

The virologic response rates (defined as a decrease in HIV plasma viral load exceeding 1.0 log10 copies/mL over 24 weeks) are summarized below, as a function of the number of PI resistance (PIR) mutations present at baseline.

Virologic Response Rates to Ritonavir-Boosted PIs
Response (%)483754297268
Response (%)
(< 5 PIR mutations)
Response (%)
(> 5 PIR mutations)

All the drugs were equally well tolerated, except for indinavir + ritonavir, which had quite a high rate of discontinuation due to toxicity (23%). This is a very good "snapshot" of the use of PIs in clinical practice in non-naive patients. It underscores the important role of resistance testing in this setting. If isolates have a limited number of mutations in the protease gene (as would be expected in patients with more extensive prior exposure to non-nucleoside reverse transcriptase inhibitors [NNRTIs] and more limited exposure to PIs), most available PIs would remain effective. However, with more advanced courses of therapy, efficacy is more modest, and the use of newer agents such as tipranavir + ritonavir seems to be favored.

The relatively preserved efficacy of saquinavir + ritonavir (an agent that has not been used extensively in recent years) is a bit surprising, but is worthy of note. It may be worth reconsidering its utility in salvage therapy, on its own or as part of double-PI regimens, for which it may be particularly well suited, based on pharmacokinetic parameters.


  1. de Mendoza C, Ribera E, Barreiro P, et al. Tipranavir/ritonavir is more effective against protease inhibitor (PI)-resistant strains than other ritonavir-boosted PI in heavily antiretroviral-experienced HIV-infected patients. In: Program and abstracts of the XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada. Abstract THPE0140.

It is a part of the publication XVI International AIDS Conference.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.